TAGAMET PREVENT TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

CIMETIDINE

Prieinama:

MEDTECH PRODUCTS INC

ATC kodas:

A02BA01

INN (Tarptautinis Pavadinimas):

CIMETIDINE

Dozė:

200MG

Vaisto forma:

TABLET

Sudėtis:

CIMETIDINE 200MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

100

Recepto tipas:

OTC

Gydymo sritis:

HISTAMINE H2-ANTAGONISTS

Produkto santrauka:

Active ingredient group (AIG) number: 0111925005; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2023-04-06

Prekės savybės

_ _
_Page 1 of 24_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
TAGAMET® PREVENT
Cimetidine Tablets
Tablet, 200 mg, Oral
USP
Histamine H
2
– Receptor Antagonist
ATC Code: A02BA01
Medtech Products Inc.
660 White Plains Rd., Suite 250
Tarrytown, NY 10591
USA
Date of Initial Authorization:
Apr 12, 2000
Date of Revision:
Mar 22, 2023
Submission Control Number: 270508
_ _
_ _
_Page 2 of 24_
RECENT MAJOR LABEL CHANGES
None.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 4
4
DOSAGE AND ADMINISTRATION
.................................................................................
4
4.1
Dosing Considerations
............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
....................................................... 5
4.5
Missed Dose
...........................................................................................................
5
5
OVERDOSAGE
................................................